Document Detail

Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients.
MedLine Citation:
PMID:  21272248     Owner:  NLM     Status:  In-Data-Review    
Sevelamer hydrochloride (SH) has been reported to aggravate metabolic acidosis and hyperkalemia. This study was performed to evaluate acid-base status and serum potassium changes after replacing SH with lanthanum carbonate (LC) in hemodialysis patients. SH was prescribed for 24 weeks in 14 stable hemodialysis patients and replaced by LC in a similar treatment schedule. Laboratory tests, including indices of acid-base status, nutrition, bone/mineral metabolism, and dialysis adequacy, were performed monthly during the study. Dialysate bicarbonate, potassium and calcium concentrations remained constant. Serum bicarbonate and pH rose, and serum potassium dropped significantly under LC. Alkaline phosphatase also decreased significantly under LC. No significant differences were observed in the other studied parameters between the two treatment periods. Control of serum phosphate was similar under both phosphate-binders and no differences were observed in calcium, Ca × P product, CRP, or lipid levels. Dialysis adequacy was constantly kept within K/DOQI target-range. Although full compliance to treatment was reported, three patients on LC complained of gastrointestinal upset and/or a metallic taste, and four had difficulty chewing the LC tablet. LC improves metabolic acidosis and hyperkalemia in hemodialysis patients previously under SH. Although both medications are well-tolerated, the gastrointestinal side-effects appear to occur more frequently with LC; a fact that, together with difficulties in chewing the tablet, may result in decreased compliance.
Vassilis Filiopoulos; Ioannis Koutis; Sofia Trompouki; Dimitrios Hadjiyannakos; Dimitrios Lazarou; Dimosthenis Vlassopoulos
Related Documents :
8177388 - Management of neurosurgical patients with hyponatremia and natriuresis.
2410068 - The effect of hydroxyurea on hemoglobin f in patients with myeloproliferative syndromes.
6206028 - Globin synthetic ratios in homozygous beta-thalassemia patients from lebanon.
6883828 - Continuous electrocardiographic monitoring in patients with sickle-cell anemia during p...
23806478 - Left ventricular dysfunction and outcome at two-year follow-up in patients with type 2 ...
12632308 - Vascularized second metacarpal-base bone graft in scaphoid non-union by the palmar appr...
Publication Detail:
Type:  Journal Article     Date:  2010-10-25
Journal Detail:
Title:  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy     Volume:  15     ISSN:  1744-9987     ISO Abbreviation:  Ther Apher Dial     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101181252     Medline TA:  Ther Apher Dial     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  20-7     Citation Subset:  IM    
Copyright Information:
© 2010 The Authors. Therapeutic Apheresis and Dialysis © 2010 International Society for Apheresis.
Nephrology Department, Amalia Fleming General Hospital, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Therapeutic apheresis in the treatment of hemolytic uremic syndrome in view of pathophysiological as...
Next Document:  Pathological role of aminolevulinate in uremic patients.